Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 690.10M | 674.14M | 630.58M | 621.99M | 609.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 690.10M | 674.14M | 630.58M | 621.99M | 609.29M |
| Cost of Revenue | -88.32M | 268.22M | -197.49M | 23.11M | 12.14M |
| Gross Profit | 778.42M | 405.93M | 828.06M | 598.89M | 597.16M |
| SG&A Expenses | 154.07M | 174.96M | 155.79M | 189.60M | 119.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 128.91M | 541.02M | -1.91M | 263.21M | 182.14M |
| Operating Income | 561.20M | 133.12M | 632.48M | 358.78M | 427.16M |
| Income Before Tax | 266.64M | 81.49M | 468.26M | 355.91M | 440.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 266.64M | 81.49M | 468.26M | 355.91M | 440.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -121.96M | -63.60M | -173.57M | -141.71M | -155.99M |
| Net Income | 144.68M | 17.88M | 294.69M | 214.21M | 284.22M |
| EBIT | 561.20M | 133.12M | 632.48M | 358.78M | 427.16M |
| EBITDA | 562.42M | 134.41M | 633.65M | 359.98M | 428.43M |
| EPS Basic | 0.32 | 0.04 | 0.67 | 0.39 | 0.66 |
| Normalized Basic EPS | 0.40 | -0.08 | 0.41 | 0.04 | 0.17 |
| EPS Diluted | 0.32 | 0.04 | 0.67 | 0.39 | 0.66 |
| Normalized Diluted EPS | 0.32 | -0.06 | 0.32 | 0.04 | 0.13 |
| Average Basic Shares Outstanding | 446.03M | 445.06M | 436.79M | 556.00M | 431.89M |
| Average Diluted Shares Outstanding | 557.00M | 556.90M | 556.84M | 556.00M | 559.61M |
| Dividend Per Share | 0.24 | 0.24 | 0.24 | 0.22 | 0.22 |
| Payout Ratio | 72.66% | 586.68% | 35.46% | 44.04% | 33.53% |